Navamedic reports double-digit Q3 growth; completes DNE Pharma acquisition and rights issue

Navamedic ASA posted double-digit revenue growth in the third quarter of 2025, driven by increases across all three business areas. The Rx segment included NOK 10.6 million in revenue from the newly acquired dne pharma business.

Financing & portfolio move

• Acquisition closed: Navamedic completed the dne pharma acquisition in July 2025.
• Rights issue: A subsequent rights issue was completed in October 2025 to support the transaction and growth plan.

“The portfolio we have acquired fits well into the Navamedic setup and provides a new focus area with growth potential—Addiction—within our Rx portfolio,” said CEO Kathrine Gamborg Andreassen. “Addiction is a growing societal challenge and Navamedic is now positioned to be at the forefront of treatment within this category.”

Q3 2025 key figures

• Operating costs: NOK 40.8m (vs. NOK 37.1m last year).
• EBIT: –NOK 0.2m, largely reflecting amortization of intangibles from the dne transaction.
• Net financial items: –NOK 3.6m.
• Profit before tax: –NOK 3.8m.
• Total cash flow (quarter): +NOK 9.1m.
• Cash balance (period-end): NOK 51.7m.

Outlook

Navamedic maintains its mid-term ambition of building a NOK 1 billion revenue company. Management points to growth across all business areas and sees additional upside from:

• the addiction-treatment portfolio acquired with dne pharma,
• the antibiotics portfolio,
• Flexilev in Orafid for Parkinson’s disease, and
• other established “hero” brands.

Presentation

Navamedic will present Q3 2025 results today at 08:30 at Haakon VIIs gate 2, Oslo. The event will be webcast:
https://navamedic.com/investors/financial-results/